Athersys Price to Free Cash Flow Ratio 2006-2021 | ATHX

Historical price to free cash flow ratio values for Athersys (ATHX) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Athersys Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 1.29 0.00
2021-06-30 1.44 $-0.37 0.00
2021-03-31 1.80 $-0.34 0.00
2020-12-31 1.75 $-0.34 0.00
2020-09-30 1.95 $-0.30 0.00
2020-06-30 2.76 $-0.25 0.00
2020-03-31 3.00 $-0.28 0.00
2019-12-31 1.23 $-0.24 0.00
2019-09-30 1.33 $-0.20 0.00
2019-06-30 1.68 $-0.21 0.00
2019-03-31 1.50 $-0.10 0.00
2018-12-31 1.44 $-0.11 0.00
2018-09-30 2.10 $-0.13 0.00
2018-06-30 1.97 $-0.13 0.00
2018-03-31 1.83 $-0.21 0.00
2017-12-31 1.81 $-0.22 0.00
2017-09-30 2.06 $-0.23 0.00
2017-06-30 1.51 $-0.25 0.00
2017-03-31 1.71 $-0.29 0.00
2016-12-31 1.53 $-0.15 0.00
2016-09-30 2.13 $-0.14 0.00
2016-06-30 2.17 $-0.11 0.00
2016-03-31 2.25 $-0.10 0.00
2015-12-31 1.03 $-0.17 0.00
2015-09-30 1.10 $-0.18 0.00
2015-06-30 1.21 $-0.22 0.00
2015-03-31 2.88 $-0.22 0.00
2014-12-31 1.58 $-0.33 0.00
2014-09-30 1.39 $-0.34 0.00
2014-06-30 1.79 $-0.35 0.00
2014-03-31 3.24 $-0.38 0.00
2013-12-31 2.50 $-0.40 0.00
2013-09-30 1.64 $-0.39 0.00
2013-06-30 1.66 $-0.41 0.00
2013-03-31 1.68 $-0.45 0.00
2012-12-31 1.06 $-0.55 0.00
2012-09-30 1.39 $-0.68 0.00
2012-06-30 1.61 $-0.75 0.00
2012-03-31 1.55 $-0.78 0.00
2011-12-31 1.73 $-0.65 0.00
2011-09-30 1.76 $-0.59 0.00
2011-06-30 2.71 $-0.52 0.00
2011-03-31 2.84 $-0.46 0.00
2010-12-31 2.47 $-0.58 0.00
2010-09-30 3.05 $-0.23 0.00
2010-06-30 2.91 $-0.26 0.00
2010-03-31 3.10 $-0.30 0.00
2009-12-31 4.13 $-0.26 0.00
2009-09-30 1.22 $-0.65 0.00
2009-06-30 0.88 $-0.76 0.00
2009-03-31 0.90 $-0.81 0.00
2008-12-31 0.45 $-0.86 0.00
2008-09-30 1.74 $-1.44 0.00
2008-06-30 2.45 $-0.67 0.00
2008-03-31 3.75 $-1.35 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.292B $0.001B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00